FDA Sees Possible Cancer Risk With Breast Implant Patients

Posted On: January 27, 2011 Author: The Office of Dr. Stuart Linder Posted In: Breast Implants, Home, Media

The study today has now been disclosed on January 26, 2011 by the FDA stating a slight but small possible risk of an anaplastic large cell lymphoma in patients who have undergone silicone and saline implants.  Approximately 60 cases of disease worldwide have been estimated in 5 to 10 million women with breast implants.  This statistical evidence has been tabulated since 1997 and given to the FDA. 

 In general, Allergan Pharmaceuticals and Johnson and Johnson (Mentor Corporation) will continue to follow patients and monitor those with this ALCL form of cancer.  This very small number of cases to me is not alarming and patients should not run out and have their implants removed nor be persuaded not to have breast enhancement or breast reconstructive surgery in the future.  I do agree that healthcare professionals should confirm all cases of ALCL with the FDA and if a patient has chronic seromas or capsular contracture with scar tissue, then the capsule should be sent to Pathology for final diagnosis for cancer.  Women should monitor their breast implants, contact their physician with any noticeable changes with scar tissue or fluid collections and that discussion with future patients of all risks should be continued.